IGM Biosciences, Inc. (IGMS)
Stock Price:
$60.92 USD
1.87 (3.17%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.87B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-61.45M |
| Shares Out |
24.22M |
| EPS (ttm) |
-26.20 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$60.92 |
| Previous Close |
$59.05 |
| Change ($) |
1.87 |
| Change (%) |
3.17% |
| Day's Open |
59.16 |
| Day's Range |
58.53 - 63.06 |
| Day's Volume |
190,148 |
| 52-Week Range |
19.43 - 89.81 |
More Stats
| Market Cap |
1.87B |
| Enterprise Value |
1.68B |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.22M |
| Float |
13.09M |
| EPS (basic) |
7.72 |
| EPS (diluted) |
-26.20 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.57M |
| Short Ratio |
6.97 |
| Short % of Float |
11.97% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
11.75 |
| Revenue |
n/a |
| Operating Income |
-64.59M |
| Net Income |
-61.45M |
| Free Cash Flow |
n/a |
| Net Cash |
184.58M |
| Net Cash / Share |
6.02 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-29.09% |
| ROE |
-49.40% |
| ROIC |
-34.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
8 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$82.33*
(35.14% upside)
Low
68.0
Current: $60.92
High
95.0
Target: 82.33
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -44.50 | -22.79 | -11.15 |
| Net Income | -43.13 | -22.71 | -11.05 |
| Shares Outstanding | 9.00 | 0.44 | 0.44 |
| Earnings Per Share | -4.80 | -51.84 | -25.24 |
| Operating Cash Flow | -45.12 | -20.04 | -10.36 |
| Capital Expenditures | -2.34 | -0.79 | -0.39 |
| Free Cash Flow | -47.45 | -20.83 | -10.74 |
| Cash & Equivalents | 225 | 1.99 | 0.48 |
| Total Debt | 14.73 | 5.03 | - |
| Net Cash / Debt | 210 | -3.04 | 0.48 |
| Assets | 261 | 3.98 | 1.39 |
| Liabilities | 21.12 | 8.89 | 1.11 |
| Book Value | 240 | -65.83 | -40.50 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
IGM Biosciences, Inc. |
| Country |
United States |
| Employees |
91 |
| CEO |
Fred M. Schwarzer |
Stock Information
| Ticker Symbol |
IGMS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IGMS |
| IPO Date |
September 18, 2019 |
Description
IGM Biosciences, a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.